Good day, ladies and gentlemen, and welcome to the CareDx Third Quarter 2017 Earnings Call. Today’s conference is being recorded. And at this time, I’d like to turn the floor over to David Clair, ICR, Investor Relations. Please go ahead.

Good afternoon, and thank you for joining us today. Earlier today, CareDx released financial results for the quarter ended September 30, 2017. The release is currently available on the company’s website at www.caredx.com. Peter Maag, Chief Executive Officer and President; and Michael Bell, Chief Financial Officer, will host this afternoon’s call. Before we get started, I would like to remind everyone that management will be making statements during this call that include forward-looking statements within the meaning of federal securities laws which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements, including, without limitation, our examination of historical operating trends, expectations regarding coverage decisions, pricing and enrollment matters and our future financial expectations are based upon current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results to differ materially from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and descriptions of the risks and uncertainties associated with our business, please see our filings with the Securities and Exchange Commission. CareDx disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise. This conference call contains sensitive information and is accurate only as of the live broadcast today, November 9, 2017. I will now turn the call over to Peter

Well thanks, David, and good afternoon, everyone. Thank you for joining us. We had an exciting third quarter. This afternoon, I will be providing an update on our recent achievements and performance as well as commentary on CareDx’s pathway to profitability. Mike will then provide additional financial details on the quarter. We have just come back from the American Society of Nephrology Meeting in New Orleans and it was exciting to see the interest in AlloSure, our new solution for rejection surveillance for kidney transplant patients. CareDx is increasingly recognized as a company making great strides in providing the latest technology for the field of transplantation with a clear focus on improving long-term outcomes for patients. During the third quarter, the CareDx team achieved several important milestones with respect to AlloSure. As a reminder, AlloSure measures donor-derived cell-free DNA to detect active organ rejection. AlloSure represents CareDx entry into the large kidney transplant surveillance diagnostic market. In the U.S. alone, there are more than 18,000 kidney transplants annually and an estimated 200,000 patients currently living with a transplanted kidney. There are approximately 10x the number of patients living with kidney transplants compared to those living with heart transplants, translating into an addressable market opportunity of greater than $2 billion annually. On August 24, Palmetto GBA, the Medicare administrator responsible for the molecular diagnostic technical assessment program commonly referred to as MolDx, announced AlloSure qualifies for Medicare coverage effective October 9, 2017. Then on September 26, CareDx announced AlloSure Medicare reimbursement will be $2,840 per test. This reimbursement rate recognizes the clinical utility and validity of our offering. Following the Medicare decision, an estimated 80% of kidney transplantations have AlloSure reimbursement coverage upon launch of the test. In our industry, it typically takes several quarters, sometimes even years and negotiations with…

Thank you, Peter. I have to say that I’m incredibly pleased with the progress the company has made since I came aboard six months ago. In addition to the launch of AlloSure, we’ve made good progress in our key financial objectives, which were to clean up the balance sheet, set out a path to profitability and improve our financial reporting and controls. We started the cleanup of the balance sheet at the beginning of the third quarter, when we announced the restructuring of our obligations related to the Allenex acquisition. And as Peter mentioned, we recently strengthened our balance sheet with an upsized public offering which was completed in October. The offering raised $18.3 million in net proceeds and resulted in us having a pro forma cash balance at close of approximately $24 million, which excludes restricted cash of $9.6 million. This has enabled us to remove the growing concern out – from our financial statements as believe our current cash balance will be sufficient for at least the next 12 months. We continue to focus on driving the company towards profitability. This drive resulted in us lowering our cash used in operations to $2.2 million in the third quarter, a further improvement compared to the second quarter’s $3.2 million rate. As Peter mentioned, given the recent AlloSure launch and AlloMap reimbursement news, we now have a path to reaching EBITDA profitability in the second half of 2018. We’re also making steady progress in improving the finance and accounting function. In addition to bringing on new hires in the last quarter, we’re working hard to remediate the material weaknesses of the company identified during 2016. And I hope to be able to provide further positive updates regarding this on future earnings calls. Turning to the P&L. Third quarter 2017 AlloMap revenue decreased 5% year-over-year to $8.2 million. As Peter referenced, adjusting for the $900,000 catch-up payments that be recognized in the third quarter of 2016, AlloMap revenue increased 6% in the third quarter 2017 from the prior year, which is in line with the 7% increase in test volume in the quarter. Our Olerup business increased 3% business year-over-year to $3.9 million. And as such, total revenue in the third quarter of 2017 was $12.2 million, representing a 2% decrease compared to the prior year’s $12.5 million. Again, adjusting for the $900,000 in the third quarter 2016 catch-up payments, total revenue increased 5% from the prior year quarter. For the third quarter 2017, our non-GAAP net loss was $3.3 million compared to a non-GAAP net loss of $2.9 million in the same period of 2016. Turning to guidance. We are tightening our revenue expectations and now anticipate full year 2017 revenue to be in the range of $47 million to $49 million. As a reminder, our revenue guidance only includes AlloMap and Olerup revenue and doesn’t include any contribution from AlloSure. With that, I’ll open up the call for questions.

[Operator Instructions] And first from Piper Jaffray, we have Bill Quirk.

Hi, thanks. Good afternoon.

Good afternoon, Bill. How are you doing?

Very well, thank you. Very well. First question, sorry, I must have missed it. But did you say $90 million to $100 million in 2019? Did I catch that correctly?

Yes, Bill. I think that we said we have an aspirational target of revenue of $90 million to $100 million in 2019.

Okay. Very good. And then just a couple of questions, Peter. First off, the 14 transplant centers that have ordered AlloSure, can you speak to whether or not multiple physicians within those have ordered AlloSure? Or is it just kind of perhaps the initial champion within those organizations trialing out the product?

Thank you very much. That’s excellent question. I think we’re early in the launch. We are right tracking towards where he wanted to be with AlloSure. I think 14 centers is slightly ahead of where we wanted to be, so we feel good. And you can probably appreciate that some centers, we have multiple clinicians ordering. And in many centers, we actually have the key opinion leader ordering AlloSure. So yes. I think most centers would have started using the test with our key opinion leaders testing – using the test.

Excellent. And then just a couple of housekeeping questions, if I may. Mike, with some of the new accounting standards coming up, presumably between the publicly issued price point for AlloMap and AlloSure and albeit a short history of collections on AlloSure, we shouldn’t have any issues with respect to accrual versus cash accounting in some of the changes that are coming into place for January 2018, correct?

Correct. The changes should make it a lot more linear with respect to what we recognize being in line with volume. And we – on AlloMap, we’ve got a very good history of payment, so that should be relatively straightforward. On AlloSure, because the payments will be by Medicare, again, that should make that relatively straightforward for us. So I’m not foreseeing any issues with the changes.

Okay, very good. And then just last housekeeping question for me. I think I know the answer to this. But Peter or Mike, there obviously continues to be some scuttlebutt around potential adjustments to PAMA pricing. And well certainly, some prices for some routine tests appear to be calculated incorrectly. I would imagine that you don’t anticipate any changes with respect to the AlloMap numbers that have come out from CMS in the preliminary document.

No. Our team is been very thoughtful in providing the analysis and the information that was requested from CMS for the PAMA pricing. And we see, actually, the pricing that came out completely in line with what we had submitted. So bar any additional information which we are not aware of, we think that the PAMA implementation will be on the $3,240 that we’ve been communicating.

Excellent, okay. Thank you very much. Nice quarter and certainly, best of luck with the AlloSure launch.

Thank you very much, Bill. No, AlloSure is truly a transformational opportunity for us.

Moving on, from Craig-Hallum, we have Kevin Ellich.

Good afternoon. Thanks for taking my question. Peter, just wanted to go back to the AlloSure launch. Yes, 14 centers, a little bit better than we expected as well. Where do you expect to end the year at in terms of the number of transplant centers? And what’s the initial reception been like? You guys said you were down in New Orleans at ASN. I guess what takeaways did you guys come away with?

I actually had the opportunity to go down there, and over lunch, invite a couple of opinion leaders. And by the evening, we had a significant group of the who is Who on kidney transplantation sitting around the room and sharing our story on AlloSure. This is a transformational product for the community that has been waiting for a new tool to improve patient surveillance. So I think we’re coming at a time where everybody’s looking at these new technologies, and what do they mean for transplantation is really what CareDx brings. In terms of the 14 centers, I think we are right where we want to be. In a bit of the outlook I think we had shared previously in last financing, where we said this will be largely driven by 35 centers adopting KOAR next year. So if he were to end, end of next year with the 40 centers having adopted AlloSure, I think that is – that would be a great success. Where we going to be ending up this year? I can tell you it’s more than 14, but I think anything else would be a bit too early for me to share. We are four weeks in and we’re very excited about the progress that we are making.

Great. And then I think in your prepared remarks, you said that you’ve actually started to receive reimbursement from Medicare for some of the AlloSure tests ordered. Is that correct?

No. I think the team has worked extremely well. And we were in close contact with Noridian. And it was great to report that we have the first AlloSures reimbursed. Mike, did you want to add?

No. It’s just that we received the first payment last week. And since then, we’re getting paid for the tests that we billed to Noridian.

Okay. So sounds like that payment came in, in a timely, timely manner. That’s great. I guess, wanted to go back to the 14 day rule comment, Peter, and the change that Medicare made to lab data service. Can you provide a little bit more color as to what that means? I think a lot of people don’t really understand that there’s other arrangements that go through the hospitals. But why will that help with adoption and compliance? And what does it mean for both AlloMap and AlloSure?

Yes. The 14-day rule basically says that now CareDx can bill Medicare directly, even on tests that are drawn from hospitals during the day of the services being provided to the patient. In the past, what we have established is in the vicinity or around the hospitals, draw sites that were drawing the AlloMap blood draw alongside days that patients were visiting the center, but in a different location. This is now not necessary anymore, and patients can actually be drawn for an AlloMap and an AlloSure alongside the regular bloodwork that they’re getting at the center. So imagine now for a kidney transplantations, whenever they are being drawn a serum creatinine, we have the opportunity to also receive an AlloSure blood draw since they’re – in many centers, serum creatinines are performed 25 times in the first year post-transplant, there are multiple opportunities where an AlloSure can be drawn alongside all the other bloodwork. So this is a very substantial change to workflow. With AlloMap, we successfully have been mitigating that with other structures, but now it becomes so much easier. And it’s great for patients that they have directly access to blood draws at the hospital, which makes it so much more convenient.

Sure. And I guess, do you know – or is there a way to think about how much of a factor it was with AlloMap adoption when this was an issue before? I mean, were doctors not ordering AlloMap or not adopting it because they would have to send patients out to a different draw station...

Anecdotally, we know that it has been an issue, but very few exception. AlloMap is a very high value test. And so the inconvenience factor of having to go to a different draw site might have been less of an issue. But it has been an issue. And of course, if you have to drive two miles in snow and ice up in the Northeast of the U.S., that had been anecdotally an issue. And it – now it’s much – so much easier. So I don’t think – it’s extremely hard for us to quantify the volume impact, but for sure, it’s a huge patient convenience factor.

Great. That’s helpful. And then my last question is – I guess thinking about – I know we have the domestic launch of AlloSure to focus on. But could you maybe talking about the pipeline in terms of the thinking about the next test you guys want to work on with cell-free DNA and also maybe even extending AlloSure into the international markets?

Yes, and I don’t think we have a detailed strategy here yet. But clearly, cell-free DNA is a pan-organ opportunity. Cell-free DNA can be tested in other organ systems. We have had some academic efforts ongoing in other transplant systems. So really, rolling out cell-free DNA for other organs will be a focus for the company. And then AlloSure ex-U.S. will be a significant opportunity because there are more kidney transplants performed outside of the U.S. than in the U.S. But we have a detailed the strategy. I think that probably, we will have to do with kitting of the product one day and then providing it through our Olerup channels. But I think we haven’t talked about in detail that strategy yet. We are – right now, we are laser-sharp-focused on the AlloSure launch. The kidney transplant opportunity is the biggest opportunity, and that’s what we are focusing on.

Got you. Thanks so much.

All right. And moving on, we have Nicholas Jansen with Raymond James.

Hey guys, congrats on a good quarter. My first question will just be on the targeted profitability discussion that you had. I just wanted to kind of get a sense of how quickly or what costs that need to be added to the model to deliver on kind of the AlloSure ramp? And if you do hit that aspirational $90 million to $100 million revenue target in 2019, what’s the margin profile and EBITDA look like under those scenarios?

You’re moving us way into next year and then beyond, Nick. Thank you so much. Great question. Obviously, this is all centered around AlloSure launch and how quickly AlloSure can ramp. I think we’re pleased with the process that we’re making progress that we are making on AlloSure. But I think then the next stage will be what’s the volume looking like for AlloSure? So I’ll turn that a bit to Mike. Mike, do you have any thoughts?

Yes, Nick. I think one of the questions that you asked was how much additional cost we need to add. And I think we’ve been consistently saying that we’ve got the existing infrastructure for AlloSure both in the lab and also on the commercial side. So our incremental costs for AlloSure are going to be relatively minimal. And therefore, we’ve been saying that if you’re modeling gross margins initially on AlloSure of 60%, then that gross profit should be dropping down to the bottom line. I think you asked about the EBITDA margin in 2019 if we you get to $100 million revenue. That would be around the 20% mark.

That’s very helpful. And then just in terms of the timing of the KOAR registry trial. How quickly do we think we can start seeing some centers operate under that? And kind of what’s the expectation of that in terms of the time line in terms of how many tests in 2018 associated with that trial?

Nick, thank you. Great questions. So we were on line to have a first patient, first visit in January next year, in the first quarter. The 35 centers, we have an aspirational goal of including all 35 centers throughout the year 2018 and then the recruitment of these patients happening within a six months timeframe. So to build that model out, it’s in December, you would have the 35th center recruiting the first patient, and then another six months recruiting these patients in the last center. Does that make sense?

Absolutely. And then my last question just on the Allenex side of the house. That piece of the business actually kind of beat our expectations a little bit in the quarter. So I just wanted to kind of get your broader thoughts on where that fits into the strategic organization of CareDx going forward. And the timeline on QTYPE.

We are super excited about building a pre-/post-transplant patient journey business because the pre-transplantation information is sometimes lost in the post-transplantation management. And I think we have the company well positioned in order to change that. I think short term, we’re really focused on launching QTYPE. This is a transformational opportunity for the pre-transplant business because it provides this rapid turnaround typing. I think we’ve been tripping up on a couple of validation efforts, especially on the ABI machine, but the team seems to have that under control now and we are looking forward to roll that solution out. I think 51 demos is a very strong number, so we feel good about the number of demonstrations that we had. But I think QTYPE is really, for next year, a growth driver for the business, which should revitalize our pre-transplantation business.

Great. And then just one quick one for Mike in terms of what’s the pro forma cash and share count as we think about exiting 2017?

The pro forma cash as you’re exiting 2017 will be around $18 million to $20 million. And from a share count perspective, after the offering, we had 27.5 million shares outstanding. So that’s where we are now.

Congrats, guys. I’ll hop back in queue.

All right. And we’ll move back to Bill Quirk with a follow-up with Piper Jaffray.

Great, thanks. One quick follow-up question. Peter, of the – going back to the 14 centers that have ordered AlloSure. Can you just explain or elaborate on that? How many of those were clinical trial sites versus non-clinical trial sites? People that have heard about AlloSure and clearly excited and wanted to be some of the first movers.

Actually surprisingly, we have a mixed bag of these 14 centers. Not all of them have been DART centers. So as we rolled through the launch, that we have found a number of centers that they’re very excited to be in the first wave. As I mentioned, I think, in the previous call, I think we have focused on 70 centers in the initial launch period, or prelaunch period, and have been able to convert 14 of those into testing centers. Of the 70 centers, obviously, all DART centers had been part of the focus. But we moved beyond DART in order to have the 14 centers tested.

And presumably all the DART centers are, if they haven’t ordered already, they are presumably going to be here in extended first wave, if you will?

Yes, no. I think I would say that those centers that we have built close relationships with are destined to be part of AlloSure. What is probably true is in some centers, we had more research-oriented clinicians joining the DART trial, and now we are moving on to the clinicians that are really doing patient management on a daily basis, that see patients in the clinic. So we have now added centers on the core focus that see many, many patients rather than being an initial phase of DART, where we focused on key opinion leaders with a big scientific reputation. We are now shifting the team focus to which are the centers that are high-volume transplant centers.

Got it. Thank you.

All right. And ladies and gentlemen, that does conclude our question-and-answer session. I’d like to turn the floor back over to Peter Maag for any additional or closing remarks.

Thank you all for joining the call. We look forward to updating everyone as we continue to commercialize AlloSure, grow our core transplantation business and progress towards profitability. Thanks again.

Ladies and gentlemen, that does conclude today’s conference. We do appreciate your participation. You may now disconnect.